December 04, 2019
1 min read

Aerie seeks European marketing authorization for Roclanda

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Aerie Pharmaceuticals has submitted a marketing authorization application for Roclanda to the European Medicines Agency, according to a press release.

Roclanda (netarsudil 0.02% and latanoprost 0.005% ophthalmic solution), known as Rocklatan in the United States, is a once-daily IOP-lowering eye drop for the treatment of open-angle glaucoma or ocular hypertension.

“In Europe, fixed-dose combinations with prostaglandins are frequently prescribed for the reduction of intraocular pressure associated with glaucoma. If approved, the combination of our Rho kinase inhibitor with a prostaglandin would be a first for Europe, and we look forward to working with the EMA in the coming months with the goal of bringing this potential new treatment to patients,” Vicente Anido Jr., PhD, Aerie chairman and CEO, said in the release.

The company previously received marketing authorization for Rhokiinsa (netarsudil ophthalmic solution 0.02%), known as Rhopressa in the United States, which predicated the Roclanda marketing authorization application submission.